Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Scrutiny of Drug Makers Abroad Faulted (Asia)

This article was originally published in PharmAsia News

Executive Summary

A preliminary report by the Government Accountability Office shows the U.S. Food and Drug Administration would inspect overseas drug manufacturers once every 13 years at its typical pace. In fact, the USFDA only has records of ever inspecting a third of the 3,249 foreign drug companies on its priority list. In 2007, the agency inspected 13 out of the 714 Chinese drug makers that may export to the U.S. Out of 410 Indian facilities that could be inspected, only 65 were observed this year. In light of these findings, U.S. pharmaceutical companies say overseas drug manufacturers should be held to domestic standards. By law, U.S. manufacturers must be inspected every two years. (Click here for more - May Require Paid Subscription

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel